Inactive Instrument

Novo Nordisk A/S Share Price SIX SWISS EXCHANGE - BLUE CHIPS SEGMENT

Equities

NOVOB

DK0060102614

Pharmaceuticals

End-of-day quote SIX SWISS EXCHANGE - BLUE CHIPS SEGMENT
- DKK - Intraday chart for Novo Nordisk A/S

Financials

Sales 2024 * 291B 41.93B 3,497B Sales 2025 * 352B 50.65B 4,224B Capitalization 4,382B 631B 52,619B
Net income 2024 * 105B 15.07B 1,257B Net income 2025 * 128B 18.39B 1,534B EV / Sales 2024 * 15.1 x
Net Debt 2024 * 22.09B 3.18B 265B Net cash position 2025 * 6.04B 869M 72.48B EV / Sales 2025 * 12.4 x
P/E ratio 2024 *
42.3 x
P/E ratio 2025 *
34.6 x
Employees -
Yield 2024 *
1.2%
Yield 2025 *
1.47%
Free-Float 70.17%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 58 01/91/01
Director of Finance/CFO 53 01/99/01
Chief Tech/Sci/R&D Officer - 01/15/01
Members of the board TitleAgeSince
Director/Board Member 62 19/15/19
Chairman 61 23/17/23
Director/Board Member 68 01/18/01
More insiders
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
More about the company